Welcome to the 123rd edition of Deep Tech Catalyst, the educational channel from The Scenarionist where science meets venture!
This week, I sat down with Jeff Uhrig, a 2x exited Deep Tech founder who is now Principal and Founder of Beech Lab. In this conversation, he reflects on his experience as CEO of Sirrus, a specialty chemicals startup acquired by Nippon Shokubai in 2017.
We explore how the company turned a promising molecule into a commercially relevant platform, and how the team navigated application discovery, customer-led development, scale-up, capital allocation, and ultimately the acquisition.
Key takeaways from the episode:
🧪 A Breakthrough Material Is Not Yet a Business
Technical performance matters, but the first challenge is often finding a way to manufacture the material at a cost and scale that make commercial adoption realistic.
🎯 The Best First Market Is the One the Company Can Reach
The team moved beyond its original adhesive thesis by looking for an application with a lower technical barrier, a clearer operational advantage, and motivated customers capable of pulling the technology through the value chain.
💰 Sell Economic Outcomes, Not Chemistry
Customers were not asked to value an unfamiliar molecule in isolation. The company translated its performance into energy savings, lower capital requirements, and a value-based pricing model built around the economics of the end application.
🤝 Customer Feedback Can Shape the Next Generation of the Platform
The second major application emerged through direct collaboration with a commercial partner, whose requirements helped the team design new molecules with improved flexibility and thermal performance.
🏭 Treat the Exit as a Strategic Threshold
The decision was not simply whether to raise more capital or sell. It was whether the company should absorb the dilution and build the capabilities required to operate at commercial scale, or allow a strategic partner to create greater leverage while preserving the value of the technology and team.
